2021
Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline
Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Früh M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB. Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline. Journal Of Clinical Oncology 2021, 40: 1356-1384. PMID: 34936470, DOI: 10.1200/jco.21.02528.Peer-Reviewed Original ResearchConceptsStage III NSCLCManagement of patientsCell lung cancerEvidence-based recommendationsLung cancerStage IIIEvidence-based guideline recommendationsUnresectable stage III NSCLCLiterature searchRecurrence-free survivalWorkup of patientsOutcomes of interestQuality of lifeAdvocacy expertsCommunity oncologyASCO guidelinesAdjuvant approachGuideline recommendationsSurgical managementMedical oncologyThoracic surgeryPulmonary oncologyExpert panel membersSystematic reviewPatients
2003
Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer
Socinski MA, Rivera MP, Detterbeck FC. Gemcitabine-Based Combinations as Preoperative Therapy in Resectable Non–Small-Cell Lung Cancer. Clinical Lung Cancer 2003, 4: s50-s55. PMID: 14720337, DOI: 10.3816/clc.2003.s.004.Peer-Reviewed Original ResearchGemcitabine-containing regimensPhase III trialsStage III NSCLCComplete surgical resectionPreoperative therapyIII trialsSurgical resectionInduction therapyLung cancerResectable non-small cell lung cancerNon-small cell lung cancerDominant recurrence patternGemcitabine-based combinationsSystemic micrometastatic diseaseCisplatin/gemcitabinePhase II trialMajority of patientsMinority of patientsCell lung cancerOverall response rateStandard of careAdjuvant chemotherapyAdvanced NSCLCII trialStage IB